Articles tagged "HLA antibodies"

2020 American Transplant Congress
The Liver Protects All? Donor Specific Antibody Formation in Heart-Liver Transplant Recipients
A. W. Rogers¹, T. N. Eagar², C. Pham¹, J. Krisl¹, B. J. Pierce¹, M. Moaddab¹, R. Ghobrial³, B. Trachtenberg⁴, A. Bhimaraj⁴, A. O. Gaber³
¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX, ²Department of Pathology, Houston Methodist Hospital, Houston, TX, ³Department of Surgery, Houston Methodist Hospital, Houston, TX, ⁴Houston Methodist Hospital, Houston, TX
*Purpose: Donor specific antibodies (DSAs) are key in the development of antibody mediated rejection (AMR). Their role in decreased patient and graft survival has been…
2020 American Transplant Congress
Epitope Analysis of Complement-Binding De Novo Donor-Specific HLA Class II Antibody
K. Yamanaka, M. Hashimoto, T. Kinoshita, Y. Fujita, S. Matsumura, T. Imanaka, A. Taniguchi, T. Yoshida, H. Kishikawa
Department of Kidney Transplantation Center, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan
*Purpose: Patients with de novo donor specific antibody (dnDSA) after kidney transplantation have a poorer prognosis than patients without dnDSA. Meanwhile, patients with dnDSA do…
2020 American Transplant Congress
Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation
J. P. Knorr, C. Kallis, D. A. Portley, A. Jeyarajasingam, P. W. Lai, G. Bradauskaite, K. Khanmoradi
Transplant Nephrology, Einstein Medical Center, Philadelphia, PA
*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…
2020 American Transplant Congress
De Novo DSA in the Setting of Stable Renal Allograft Function Does Not Impair Long-Term Graft Survival
R. Knight¹, D. T. Nguyen², E. A. Graviss², O. Gaber¹
¹Surgery, Houston Methodist Hospital, Houston, TX, ²Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX
*Purpose: To determine the long-term outcome of renal allograft recipients with de novo DSA (dnDSA) in the setting of stable allograft function.*Methods: A single-center review…
2020 American Transplant Congress
The Impact of Epitope Mismatch Load and Shared Targeting Epitopes between De Novo Donor Specific Antibody (DSA) and Non-DSA Third Party HLA Antibody on Lung Transplantation Outcomes
A. Zhang¹, D. Good¹, D. Thomas¹, J. Allen¹, K. McCurry², M. Budev²
¹Allogen Laboratories, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
*Purpose: Rapid advancements in HLA typing and antibody identification technologies allow for enhanced HLA compatibility assessment at the epitope level to aid in the reduction…
2020 American Transplant Congress
Are HLA-DQ De Novo Donor-Specific Antibodies a Risk Factor for Acute Humoral Rejection?
R. Hod Dvorai¹, C. A. Hubbell¹, M. R. Laftavi², R. Shahbazov², B. Gallay³, O. G. Pankewycz³
¹Pathology, SUNY Upstate Medical University, Syracuse, NY, ²Surgery, SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
*Purpose: To identify HLA-DQ de novo donor-specific antibodies (dnDSA) characteristics associated with acute humoral rejection (ABMR) and response to treatment.*Methods: We performed a retrospective analysis…
2020 American Transplant Congress
Mid-Term Outcomes after Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
M. Okada¹, T. Tomosugi¹, T. Hiramitsu¹, S. Narumi¹, Y. Watarai¹, A. Kanda¹, K. Futamura¹, N. Goto¹, A. Takeda²
¹Nagoya Daini Red Cross Hospital, Nagoya, Japan, ²Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
*Purpose: De novo donor-specific HLA antibody (DSA) and antibody-mediated rejection (ABMR) are strongly associated with late allograft loss in renal transplant recipients. However, the impact…
2020 American Transplant Congress
Clazakizumab (Anti-IL-6) Induces Foxp3+ Tregs in Highly HLA Sensitized Patients Desensitized for HLAi Transplantation (NCT03380962)
S. C. Jordan, S. Ge, N. Ammerman, M. Toyoda, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamson, C. Myers, K. Lim, J. Choi, A. Vo
Cedars Sinai Medical Ctr, West Hollywood, CA
*Purpose: Interleukin-6 is an important inflammatory cytokine. In addition, it acts as a growth factor for B-cells, plasma cells and Th17 cells, inhibiting FoxP3+ Treg…
2019 American Transplant Congress
Comparing Antibody-Mediated Rejection with or without Detectable DSA: Similar Pathology and Similar Poor Prognosis
G. Einecke¹, J. Reeve², P. F. Halloran³
¹Dpt. of Nephrology, Hannover Medical School, Hannover, Germany, ²Dpt. of Laboratory Medicine and Pathology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada, ³Dpt. of Nephrology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada
*Purpose: Banff guidelines require the detection of donor-specific antibodies (DSA) in addition to microvascular inflammation (MVI) for a diagnosis of antibody-mediated rejection (ABMR), but MVI…
2019 American Transplant Congress
Impact of HLA-DR Matching on HLA-DQ Matching Status and the Development of Anti-HLA-DQ De Novo DSA under Calcineurin Inhibitor or Belatacept Immunosuppression
V. Jucaud¹, H. Gebel², R. Bray², M. Polinsky³, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Emory University, Atlanta, GA, ³Bristol-Myers Squibb, Princeton, NJ
*Purpose: De novo donor-specific HLA antibodies (dnDSA) that develop after kidney transplantation target more frequently allo-HLA-DQ antigens in comparison to other allo-HLA antigens. Yet, organ…